DMRA · Damora Therapeutics Inc
United States · RS rating 49 · As of 2026-11-03
| Price | 22.08 USD |
|---|---|
| 1-day change | +2.2% |
| RS rating (overall / 1M / 3M / 12M) | 49 / 81 / 22 / 97 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 37 / 19 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +37.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +35.3% |
| Market cap (USD) | $1.5B |